# A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

> **NCT02981342** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 106 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** LY3023414
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02981342
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-12
- **Primary completion:** 2018-04-20
- **Final completion:** 2018-11-09
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981342, "A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02981342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*